Evidence map›Paper›PMID 40149875›Full record

ArticleBiomolecules2025

In Vitro and In Vivo Evaluation of the De Novo Designed Antimicrobial Peptide P6.2 Against a KPC-Producing

Melina M B Martinez, Merlina Corleto, Melanie Weschenfeller, Santiago Urrea Montes, Camila N Salomón, Natalia Gonzalez, Matías Garavaglia, Diego Faccone, Paulo C Maffía

Abstract read
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Melina M B MartinezLaboratorio de Aplicaciones Biotecnológicas y Microbiología (LAByM), Secretaría de Investigación, Universidad Nacional de Hurlingham (UNAHUR), Hurlingham 1688, Buenos Aires, Argentina.ORCID 0000-0002-4007-8721
Merlina CorletoLaboratorio de Aplicaciones Biotecnológicas y Microbiología (LAByM), Secretaría de Investigación, Universidad Nacional de Hurlingham (UNAHUR), Hurlingham 1688, Buenos Aires, Argentina.
Melanie WeschenfellerLaboratorio de Aplicaciones Biotecnológicas y Microbiología (LAByM), Secretaría de Investigación, Universidad Nacional de Hurlingham (UNAHUR), Hurlingham 1688, Buenos Aires, Argentina.
Santiago Urrea MontesLaboratorio de Aplicaciones Biotecnológicas y Microbiología (LAByM), Secretaría de Investigación, Universidad Nacional de Hurlingham (UNAHUR), Hurlingham 1688, Buenos Aires, Argentina.
Camila N SalomónLaboratorio de Aplicaciones Biotecnológicas y Microbiología (LAByM), Secretaría de Investigación, Universidad Nacional de Hurlingham (UNAHUR), Hurlingham 1688, Buenos Aires, Argentina.
Natalia GonzalezLaboratorio de Aplicaciones Biotecnológicas y Microbiología (LAByM), Secretaría de Investigación, Universidad Nacional de Hurlingham (UNAHUR), Hurlingham 1688, Buenos Aires, Argentina.
Matías GaravagliaLaboratorio de Aplicaciones Biotecnológicas y Microbiología (LAByM), Secretaría de Investigación, Universidad Nacional de Hurlingham (UNAHUR), Hurlingham 1688, Buenos Aires, Argentina.
Diego FacconeConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires 1425, Argentina.
Paulo C MaffíaLaboratorio de Aplicaciones Biotecnológicas y Microbiología (LAByM), Secretaría de Investigación, Universidad Nacional de Hurlingham (UNAHUR), Hurlingham 1688, Buenos Aires, Argentina.ORCID 0000-0001-7423-2646

Funding

CONICET-UNAHUR PIP CONICET 2021-2023 GI 11220200101277CO ; PIO UNAHUR-CONICET 29020220100003CO
6 · The paper itself

Abstract

The antimicrobial peptide P6.2 was previously de novo designed as an alpha helix cationic amphipathic molecule. In previous work, we have shown that this peptide displayed significant antimicrobial activity against both Gram-positive (

Indexed as

Anti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial Peptidesbeta-LactamasesPseudomonas aeruginosaA549 CellsAnimalsBacterial ProteinsBiofilmsHumansMeropenemMiceMicrobial Sensitivity TestsMothsPseudomonas InfectionsRAW 264.7 CellsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesBacterial Proteinsbeta-LactamasesMeropenemantimicrobial peptidesKPCmeropenemPseudomonas aeruginosa

Identifiers

PMID40149875
PMCPMC11940343

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.